International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(24), P. 13569 - 13569
Published: Dec. 18, 2024
In
2024,
the
United
States
was
projected
to
experience
2
million
new
cancer
diagnoses
and
approximately
611,720
cancer-related
deaths,
reflecting
a
broader
global
trend
in
which
cases
are
anticipated
exceed
35
by
2050.
This
increasing
burden
highlights
ongoing
challenges
treatment
despite
significant
advances
that
have
reduced
mortality
31%
since
1991.
Key
obstacles
include
disease’s
inherent
heterogeneity
complexity,
such
as
resistance,
stem
cells,
multifaceted
tumor
microenvironment
(TME).
The
TME—comprising
various
immune
blood
vessels,
biochemical
factors—plays
crucial
role
growth
resistance
therapies.
Recent
innovations
treatment,
particularly
field
of
immuno-oncology,
leveraged
insights
into
TME
interactions.
An
emerging
example
is
FDA-approved
therapy
using
tumor-infiltrating
lymphocytes
(TILs),
demonstrating
potential
cell-based
approaches
solid
tumors.
However,
TIL
just
one
many
strategies
being
explored.
review
provides
comprehensive
overview
focusing
on
how
novel
therapies
targeting
or
harnessing
components
could
enhance
efficacy
address
persistent
care.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: July 17, 2024
Pancreatic
adenocarcinoma,
a
clinically
challenging
malignancy
constitutes
significant
contributor
to
cancer-related
mortality,
characterized
by
an
inherently
poor
prognosis.
This
review
aims
provide
comprehensive
understanding
of
pancreatic
adenocarcinoma
examining
its
multifaceted
etiologies,
including
genetic
mutations
and
environmental
factors.
The
explains
the
complex
molecular
mechanisms
underlying
pathogenesis
summarizes
current
therapeutic
strategies,
surgery,
chemotherapy,
emerging
modalities
such
as
immunotherapy.
Critical
pathways
driving
cancer
development,
KRAS,
Notch,
Hedgehog,
are
discussed.
Current
radiation,
discussed,
with
emphasis
on
their
limitations,
particularly
in
terms
postoperative
relapse.
Promising
research
areas,
liquid
biopsies,
personalized
medicine,
gene
editing,
explored,
demonstrating
potential
for
enhancing
diagnosis
treatment.
While
immunotherapy
presents
promising
prospects,
it
faces
challenges
related
immune
evasion
mechanisms.
Emerging
directions,
encompassing
CRISPR/Cas9
genome
computational
intelligence
applications,
hold
promise
refining
diagnostic
approaches
interventions.
By
integrating
insights
from
genetic,
molecular,
clinical
research,
innovative
strategies
that
improve
patient
outcomes
can
be
developed.
Ongoing
these
fields
holds
advancing
treatment
this
formidable
malignancy.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(2), P. 811 - 811
Published: Jan. 19, 2025
Colorectal
cancer
(CRC)
is
one
of
the
most
common
malignant
tumors,
characterized
by
a
high
incidence
and
mortality
rate.
Macrophages,
as
key
immune
cell
type
within
tumor
microenvironment
(TME),
play
role
in
evasion
progression
CRC.
Therefore,
identifying
macrophage
biomarkers
great
significance
for
predicting
prognosis
CRC
patients.
This
study
integrates
scRNA-seq
bulk
RNA-seq
data
to
identify
macrophage-related
genes
By
applying
comprehensive
machine
learning
framework,
prognostic
signature
(MRPS)
was
constructed
15
with
values.
The
MRPS
demonstrated
strong
predictive
performance
across
multiple
datasets,
effectively
stratifying
high-risk
low-risk
patients
terms
overall
survival
(OS)
disease-specific
(DSS).
Furthermore,
analysis
revealed
significant
differences
between
groups
infiltration
levels
checkpoint
gene
expression
patterns.
Drug
screening
identified
several
small
molecules,
including
Bortezomib
Mitoxantrone,
potential
therapeutic
options
Pseudotime
trajectory
further
highlighted
comprising
differentiation.
provides
powerful
tool
personalized
prediction
patients,
offering
new
insights
into
macrophage-driven
mechanisms
strategies.
Biology,
Journal Year:
2025,
Volume and Issue:
14(2), P. 174 - 174
Published: Feb. 8, 2025
Breast
cancer
(BC)
remains
a
significant
global
health
challenge,
highlighting
the
need
for
continued
research
into
novel
risk
factors,
diagnostic
approaches,
and
personalized
treatments.
Among
emerging
viral
infections
have
been
implicated
as
potential
contributors
to
breast
carcinogenesis
BC
progression.
Recent
evidence
suggests
that
specific
oncogenic
strains
of
human
cytomegalovirus
(HCMV)
may
capacity
transform
mammary
epithelial
cells.
This
review
assesses
clinical
data
regarding
HCMV
presence
in
both
tumor
non-tumor
tissues,
examining
role
oncoproteins
development
Current
findings
indicate
higher
prevalence
infection
carcinomas
compared
associated
with
an
elevated
BC.
Additionally,
HCMV-driven
model
proposed
here
activate
multiple
pathways,
fostering
cell
proliferation,
survival,
development.
A
deeper
understanding
could
enhance
stratification
support
creation
targeted
therapeutic
strategies.
Current Oncology,
Journal Year:
2025,
Volume and Issue:
32(3), P. 143 - 143
Published: Feb. 28, 2025
Breast
cancer
is
the
most
common
type
of
in
women
and
second
leading
cause
death
by
cancer.
Despite
recent
advances,
mortality
rate
remains
high,
underlining
need
to
develop
new
therapeutic
approaches.
The
complex
interaction
between
cells
tumor
microenvironment
(TME)
crucial
determining
progression,
therapy
response,
patient
prognosis.
Understanding
role
immune
carcinogenesis
progression
can
help
improve
targeted
options,
increasing
likelihood
a
favorable
Therefore,
this
review
aims
critically
analyze
cells,
emphasizing
clinical
implications.
Additionally,
we
explore
advances
immunotherapies,
with
focus
on
checkpoint
inhibitors.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: Feb. 28, 2025
Breast
cancer
(BC)
is
the
most
common
in
women
and
a
leading
cause
of
cancer-related
mortality.
Despite
advances
screening
treatment,
outcomes
for
advanced
or
recurrent
BC
remain
poor,
highlighting
need
new
strategies.
Recent
research
emphasizes
tumor
microenvironment
(TME),
particularly
tumor-associated
macrophages
(TAMs),
as
key
drivers
growth,
metastasis,
resistance
to
therapy.
The
presence
M2-like
TAMs
TME
promotes
immune
evasion
progression
across
subtypes.
This
review
summarizes
classification,
their
role
BC,
emerging
therapies
targeting
TAMs,
including
depletion,
inhibition
recruitment,
reprogramming
from
pro-tumoral
M2
anti-tumoral
M1
phenotypes.
Targeting
offers
promising
strategy
improve
treatment
outcomes.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: April 2, 2025
The
intricate
interaction
between
skeletal
muscle
biomechanics,
the
tumor
microenvironment,
and
immunotherapy
constitutes
a
pivotal
research
focus
oncology.
This
work
provides
comprehensive
review
of
methodologies
for
evaluating
including
handheld
dynamometry,
advanced
imaging
techniques,
electrical
impedance
myography,
elastography,
single-fiber
experiments
to
assess
quality
performance.
Furthermore,
it
elucidates
mechanisms,
applications,
limitations
various
modalities,
immune
checkpoint
inhibitors,
adoptive
cell
therapy,
cancer
vaccines,
combined
chemoimmunotherapy,
while
examining
their
effects
on
function
systemic
responses.
Key
findings
indicate
that
although
is
effective
in
augmenting
antitumor
immunity,
frequently
induces
muscle-related
adverse
such
as
weakness,
fatigue,
or
damage,
primarily
mediated
by
cytokine
release
activation.
underscores
significance
niches
within
microenvironment
influencing
treatment
outcomes
proposes
strategies
optimize
therapy
through
personalized
regimens
combinatorial
approaches.
highlights
need
further
formation
interactions
muscle-tumor.
Our
crucial
advancing
efficacy
immunotherapy,
reducing
effects,
ultimately
improving
survival
rates
life
patients
with
cancer.
Cancers,
Journal Year:
2025,
Volume and Issue:
17(9), P. 1455 - 1455
Published: April 26, 2025
Objective:
Lung
adenocarcinoma
(LUAD)
remains
a
leading
cause
of
cancer-related
mortality,
particularly
in
advanced
stages.
This
study
investigates
the
anticancer
mechanisms
calycosin,
an
isoflavonoid
derived
from
Astragalus
membranaceus,
LUAD.
Methods:
Using
integrative
approaches
including
bulk
and
single-cell
RNA
sequencing,
network
pharmacology,
molecular
docking,
we
identified
SMAD3
as
critical
biomarker
associated
with
LUAD
staging
prognosis.
Results:
Calycosin
targets
SMAD3,
modulating
NOTCH
signaling
pathway
monocytes/macrophages
to
suppress
tumor
growth,
invasion,
immune
evasion.
Enrichment
analyses
revealed
significant
involvement
components
SMAD3-correlated
genes,
advanced-stage
Single-cell
sequencing
further
demonstrated
enrichment
tumor-associated
monocytes/macrophages.
Additionally,
KMT2A
was
key
transcriptional
regulator
these
cells.
Conclusions:
These
findings
highlight
potential
effects
calycosin
provide
novel
insights
into
targeting
tumor–immune
microenvironment
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: May 2, 2025
Cancer
immunotherapy,
which
leverages
the
immune
system
to
target
neoplastic
cells,
has
undergone
significant
transformation
in
recent.
However,
immunotherapy
may
have
negative
effects
on
skeletal
muscle
function,
causing
wasting
and
functional
decline
cancer
patients.
In
this
study,
we
review
mechanisms
by
influences
muscle,
focusing
immune-related
myositis,
inflammation,
metabolic
alterations
within
tumor
microenvironment
(TME).
The
key
methodologies,
including
biomechanical
assessment
techniques
such
as
electrical
impedance
myography
ultrasound
imaging,
are
discussed
provide
valuable
insights
into
process
that
maintain
integrity
function
patients
receiving
immunotherapy.
Moreover,
dual
of
suppression
damage
described,
revealing
significance
inflammatory
cytokines,
checkpoints,
disturbances
TME.
Importantly,
propose
combination
therapies
integrating
nutritional
interventions
or
anti-inflammatory
potential
approaches
for
mitigating
wasting.
This
study
highlights
need
deeper
investigations
optimize
improve
its
efficacy
preserving
health,
thereby
improving
patient
outcomes
quality
life.